Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Filiberto Cedeno Laurent

Dermatology Katy, TX Medical Doctor

NPI 1669737011 CMS profile 638440

3030 S Mason Rd, Katy, TX 77450

Open in the dashboard

General payments

$36,501

850 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Filiberto Cedeno Laurent of Katy, TX is reported in the CMS Open Payments database as having received $36,501 across 850 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,184 225
2024 General $15,118 224
2023 General $3,159 175
2022 General $1,751 94
2021 General $1,314 79
2020 General $442 24
2019 General $534 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Filiberto Cedeno Laurent
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Filiberto Cedeno Laurent were reported at $14,184. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Filiberto Cedeno Laurent Dermatology median Middle half National median
2019 $534 $454 $129–$1,240 $163
2020 $442 $235 $81–$756 $114
2021 $1,314 $377 $108–$1,108 $132
2022 $1,751 $514 $143–$1,391 $149
2023 $3,159 $607 $159–$1,674 $160
2024 $15,118 $751 $204–$1,903 $164
2025 $14,184 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $12,793 53 payments
  2. E.R. Squibb & Sons, L.L.C. $6,007 31 payments
  3. Genzyme Corporation $4,186 41 payments
  4. AbbVie, Inc. $2,061 144 payments
  5. Regeneron Healthcare Solutions, Inc. $1,710 57 payments
  6. Janssen Biotech, Inc. $1,132 78 payments
  7. Lilly USA, LLC $1,125 60 payments
  8. Revance Therapeutics, Inc. $1,097 14 payments
  9. Arcutis Biotherapeutics, Inc. $1,070 63 payments
  10. Incyte Corporation $719 53 payments
  11. Other $4,601 256 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,288 836 payments
  2. Consulting Fee $11,386 7 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,615 2 payments
  4. Travel and Lodging $1,132 4 payments
  5. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. CIBINQO $12,633 44 payments
  2. DUPIXENT Immunology $4,352 46 payments
  3. SOTYKTU $2,002 25 payments
  4. DUPIXENT Inflammation And Immunology $1,387 45 payments
  5. DAXXIFY $1,097 14 payments
  6. TREMFYA $924 67 payments
  7. RINVOQ $912 68 payments
  8. TALTZ $798 45 payments
  9. Zoryve $751 52 payments
  10. SKYRIZI $719 46 payments
  11. Other $9,084 520 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

393

Median for Dermatology: 534

Drug cost

$20,615

Median for Dermatology: $67,151

Branded share of claims

3.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zoryve Roflumilast Brand 13 $12,344
Clobetasol Propionate Generic 45 $1,689
Tranexamic Acid Generic 22 $1,389
Minoxidil Generic 95 $1,348
Fluocinonide Generic 29 $912
Doxycycline Hyclate Generic 23 $854
Ketoconazole Generic 45 $633
Triamcinolone Acetonide Generic 35 $381
Finasteride Generic 19 $260
Spironolactone Generic 11 $250

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$40,474

Medicare's payments for the services billed

Medicare patients

176

Average age 73

Services billed

1,407

104 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 45%
Ischemic heart disease 31%
Osteoporosis 26%
Diabetes 21%
Cancer 20%
Chronic kidney disease 15%
Atrial fibrillation 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CIBINQO
$7,432 — —
DUPIXENT
$4,077 — —
DAXXIFY
$639 — —
TREMFYA
$419 — —
Zoryve
$368 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

850 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record